![](https://investorshub.advfn.com/uicon/52515.png?cb=1559224406)
Thursday, December 09, 2021 5:38:33 PM
For those of you new to DARE, wondering when to sell (or buy) this stock.
First, Dare is a phenomenal, one of a kind company, not only in the biotech industry, but when compared to other tickers from any field or industry. Within its own industry, biotech clinical stage pharmas (well, not any more since they now move towards commercialization as well), DARE is a rare find, an exceptional company in several ways. Here are a few things you should know about it:
1. Vision: this is a company that has a very very clear identity, knows exactly what it is aiming for, and does NOT get distracted. This is very uncommon in biotech pharmas. As companies develop drugs, they "stumble" upon new findings that open doors to new ideas for drugs, development, etc. Covid is the best, but not the only, example. SOOOOO many companies decided to take a shot at finding a cure/vaccine/testing device for Covid, moving their focus away from their original pipeline. Not DARE, they never flinched. Stayed focused on their goals all the way through.
The vision of the company is practical, smart and geared to achieving rapid financial success. This is also a rare find in biotech pharmas. The company first thought about how to make money, then about how to develop the products, not the other way around.
What do they do differently? They do NOT develop new drugs. Instead, they take EXISTING drugs and find use for them in their specific niche: women's health.
That is a big advantage, because it allows them to receive approvals in a much certain and easier path, since they are not seeking to approve a totally new drug, simply a drug already approved, for a different use.
This way, staying focused on women's health only, bringing a team together that specialized in that specific niche and then finding new ways to use drugs that already went through an approval process, DARE has been able to push its pipeline extremely fast all the way to approval.
2. Leadership: show me another CEO with a proven track record of constant success earning less than 500K per year. The woman leading Dare is the ultimate professional. Doesn't look for any free meals, she is going to earn those billions with the results she achieves, not by abusing shareholders money. Excellent speaker, excellent deal-maker, she is first and foremost a businesswoman. So many companies in the sector are run by scientists who, smart as they might be, are terrible CEO's. Here we have the opposite, a talented, humble, sharp woman that knows her business and lets scientist take care of the lab while she takes excellent care of our money.
3. Pipeline: DARE just approved its first product, but ALL the products in the pipeline are very very promising. There are good news scheduled for this month yet, let alone Q1 of 2022. Just to give an example everyone can understand: they are using the same substance that Viagra is made of, to develop a Viagra for women. Again, not trying to make something new, just take something that already exists (viagra) and give it a use for women. And yes, this is a huge thing. Just like men, women are unable to "feel" pleasure at a certain age, etc. It's in fact the same issue that men face, just without the embarrassment. But it is a huge market for a product that women simply don't have today. And that, is just one of the products DARE is developing.
4. Partnerships: Take all the above, mix them together, and what do you get? A company that knows how to, and is not afraid of, making profitable partnerships. That is why they are already partnered with the Bill Gates Foundation, Bayer, and the Kennedy-Shriver Center. Their CEO doesn't make the same mistakes many small new pharmaceutical companied do, she gets to work and makes fast, meaningful partnerships to sustain the company and allow its rapid growth.
5. So, when should you sell? Or buy? Simple: buy now. This stock is extremely undervalued even if it jumps to 5 or 6. Getting to double figures next year is a very strong probability. And right now it's at about 3. The stock has a history of moderate price increase following big news. Contrary to most stock that have a sudden big jump, DARE in the past has moved moderately after a big announcement, only to gain traction in the following days.
And don't sell. DARE will announce a commercialization partnership for its new drug this month. And it is set to announce results for one of its clinical trials this month. The price will continue to grow into 2022. Hold and be amply rewarded.
I'm not a financial advisor. I have been holding a long position in DARE.
The dumbest people I know are those who know it all.
Malcolm Forbes
Recent DARE News
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% • GlobeNewswire Inc. • 08/26/2024 12:00:00 PM
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:01:31 PM
- Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update • GlobeNewswire Inc. • 08/12/2024 08:01:00 PM
- Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 12:05:26 PM
- Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 07/19/2024 12:00:00 PM
- Daré Bioscience Announces Reverse Stock Split • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:05:24 PM
- Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:35 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:12:44 PM
- Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM